KPTI - Karyopharm Therapeutics Inc.
IEX Last Trade
0.6079
0.003 0.477%
Share volume: 15,136
Last Updated: Thu 26 Dec 2024 08:28:07 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$0.60
0.00
0.48%
Fundamental analysis
41%
Profitability
50%
Dept financing
25%
Liquidity
67%
Performance
30%
Performance
5 Days
-3.44%
1 Month
-32.06%
3 Months
-15.78%
6 Months
-40.50%
1 Year
-33.07%
2 Year
-76.01%
Key data
Stock price
$0.61
DAY RANGE
$0.59 - $0.61
52 WEEK RANGE
$0.62 - $1.95
52 WEEK CHANGE
-$35.56
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Richard A. Paulson
Region: US
Website: karyopharm.com
Employees: 380
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: karyopharm.com
Employees: 380
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Karyopharm Therapeutics Inc. discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries.
Recent news